CLINICAL_TRIALS
trial_result
· 2026-02-10
Clinical Trial Update: Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients [Phase 1, Phase 2]
Summary
A Phase 1/2 study evaluating LT5001 for uremic pruritus in hemodialysis patients was terminated; safety results were posted in February 2026.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Lumosa Therapeutics Co., Ltd. | Conditions: Uremic Pruritus | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-02-10